Previous studies have demonstrated that high mobility group A proteins have a critical role on the onset of human pituitary adenomas. Indeed, both high mobility group A (HMGA) genes are overexpressed in pituitary adenomas, and consistently transgenic mice overexpressing either the Hmga1 or the Hmga2 gene develop mixed growth hormone/prolactin (GH-PRL)-secreting pituitary adenomas. Trisomy of chromosome 12, where HMGA2 is located, and/or amplification of the HMGA2 gene locus account for the HMGA2 overexpression in most human prolactinomas. Conversely, HMGA1 overexpression is not associated to any rearrangement or amplification of the HMGA1 locus. We have first identified micro RNAs (miRNAs) able to target both HMGA1 and HMGA2 messenger RNAs. Then, all of these miRNAs have been found downregulated in pituitary adenomas of different histotypes, compared with normal pituitary. Interestingly, their downregulation was also observed in nonfunctioning pituitary adenomas where HMGA2 overexpression is not associated to any alteration of the HMGA2 locus. Functional studies show that all these HMGA-targeting miRNAs inhibit the proliferation of the rat pituitary adenoma cell line GH3. Therefore, these results indicate that the downregulation of the miRNAs able to target the HMGA genes could contribute to increase HMGA protein levels in human pituitary adenomas, and then to pituitary tumorigenesis.
Previous studies have demonstrated that high mobility group A proteins have a critical role on the onset of human pituitary adenomas. Indeed, both high mobility group A (HMGA) genes are overexpressed in pituitary adenomas, and consistently transgenic mice overexpressing either the Hmga1 or the Hmga2 gene develop mixed growth hormone/prolactin (GH-PRL)-secreting pituitary adenomas. Trisomy of chromosome 12, where HMGA2 is located, and/or amplification of the HMGA2 gene locus account for the HMGA2 overexpression in most human prolactinomas. Conversely, HMGA1 overexpression is not associated to any rearrangement or amplification of the HMGA1 locus. We have first identified micro RNAs (miRNAs) able to target both HMGA1 and HMGA2 messenger RNAs. Then, all of these miRNAs have been found downregulated in pituitary adenomas of different histotypes, compared with normal pituitary. Interestingly, their downregulation was also observed in nonfunctioning pituitary adenomas where HMGA2 overexpression is not associated to any alteration of the HMGA2 locus. Functional studies show that all these HMGA-targeting miRNAs inhibit
Introduction
Autoptic and radiological imaging studies have demonstrated that pituitary adenomas are very common in the general population, accounting for 10-15% of all intracranial tumors (Kovacs and Horvath, 1986; Monson, 2000; Daly et al., 2009; Melmed, 2011) . Pituitary adenomas are clinically classified on the basis of their hormonal activity in vivo. Prolactin (PRL)-, gonadotropin (luteinizing hormone/follicle-stimulating hormone)-and growth hormone (GH)-secreting adenomas are the most frequent type of pituitary adenomas, whereas adenocorticotroph (ACTH (adrenocorticotropic hormone))-and tireotroph (TSH (thyroid-stimulating hormone))-secreting adenomas are very rare (Daly et al., 2006 (Daly et al., , 2009 Melmed, 2011) . Moreover, about onethird of pituitary adenomas are not associated to hormone hypersecretion, and are classified as nonfunctioning pituitary adenomas (NFPA) (Daly et al., 2006 (Daly et al., , 2009 Fernandez et al., 2010) . Commonly, both functioning and nonfunctioning adenomas are noninvasive, and their morbidity is mainly because of inappropriate secretion of pituitary hormones or symptoms of an intracranial mass, such as visual disturbance and headaches (Melmed, 2011) .
Several studies indicate that high mobility group A (HMGA) proteins have a causal role in pituitary cell transformation. HMGAs are a family of small nonhistone chromatin proteins that include four members, HMGA1a, HMGA1b, HMGA1c (encoded by the HMGA1 gene through alternative splicings) and HMGA2 (encoded by the homonymous gene) (Johnson et al., 1989) . HMGA proteins do not have transcriptional activity per se, however by interacting with the transcriptional machinery they alter the chromatin structure and, thereby, regulate, negatively or positively, the transcriptional activity of several genes and micro RNAs (miRNAs) (Thanos and Maniatis, 1992; Thanos et al., 1993; De Martino et al., 2009a) .
HMGA expression is almost undetectable in differentiated adult tissues, whereas it is expressed highly during embryogenesis Chiappetta et al., 1996) . Conversely, HMGA overexpression is a constant feature of human malignant neoplasms, and rearrangements of the HMGA genes are frequently associated with human benign tumors of mesenchymal origin Schoenmakers et al., 1995; . Several studies have demonstrated that HMGA proteins have a critical role in neoplastic transformation. In fact, blockage of HMGA synthesis prevents rat thyroid cell transformation by murine-transforming retroviruses (Berlingieri et al., 1995 (Berlingieri et al., , 2002 , and an adenovirus carrying the HMGA1 gene in the antisense orientation induces apoptotic cell death in anaplastic human thyroid carcinoma cell lines, but not in normal thyroid cells (Scala et al., 2000) . Moreover, transgenic mice overexpressing the Hmga1 or the Hmga2 gene under an ubiquitous promoter develop several malignant or benign neoplasias, including mixed GH/PRL pituitary adenomas (Baldassarre et al., 2001; Fedele et al., 2002 Fedele et al., , 2005 . The involvement of the HMGA proteins also in human pituitary adenomas was further confirmed by the observed overexpression of both HMGA genes in these neoplasias (Finelli et al., 2002; Pierantoni et al., 2005; De Martino et al., 2009b; Wang et al., 2010) . In the case of HMGA2, its overexpression is associated, in most of the PRL tumors, but less frequently in NFPAs, with gain of chromosome 12 (trisomy/tetrasomy), the most frequent cytogenetic alteration in PRL adenomas, and overrepresentation of the HMGA2 locus (region 12q14-15) or structural rearrangements of chromosome 12 . Conversely, no rearrangement or amplification of the HMGA1 locus have been detected in pituitary adenomas, even though HMGA1 overexpression is a constant feature of these tumors (De Martino et al., 2009b; Wang et al., 2010) .
Recent studies have shown that HMGA protein levels are regulated by miRNAs (Lee and Dutta, 2007; De Martino et al., 2009a) , a class of small (19-25 nucleotides) noncoding RNAs involved in temporal and tissuespecific eukaryotic gene regulation (Lagos-Quintana et al., 2002) by binding the 3 0 -untranslated region (UTR) of target messenger RNAs (mRNAs) and inducing mRNA degradation or inhibition of its translation (Bartel, 2004; Calin and Croce, 2006) . Indeed, the loss of HMGA2 3 0 -UTR, frequently detected in benign tumors of mesenchymal origin, results in the lack of inhibitory control of HMGA2 expression by different miRNAs (Hebert et al., 2007; Lee and Dutta, 2007) , thereby leading to HMGA2 protein overexpression that accounts for cell transformation.
Therefore, the aim of our work has been to investigate whether HMGA1/2 overexpression occurring in human pituitary adenomas may be also dependent on altered expression of miRNAs that are able to target the HMGA1/2 genes. The validation of such a hypothesis would account for the overexpression of the HMGA proteins in NFPAs, where modifications at the HMGA2 locus are rarely observed, and in all the pituitary adenomas where the HMGA1 overexpression is associated neither to rearrangements nor to amplification of the HMGA1 locus.
Starting from a bioinformatic approach using the miRo' web system (Lagana`et al., 2009, http 
Results

Identification of HMGA-targeting miRNAs
In order to identify potentially conserved miRNAs being able to downmodulate the expression of both the HMGA proteins, we used the miRo' web system that includes Targetscan, Pictar and Miranda, and provides miRNA phenotype associations in humans (Laganaè t al., 2009 ). This analysis identified miR-15ab, miR-16, miR-26ab, miR-196ab and Let-7a as potential HMGAtargeting miRNAs. Interestingly, the targeting sites of these HMGA-targeting miRNAs on the 3 0 -UTR of HMGA1 and HMGA2 are extremely conserved in human, mouse and rat. Moreover, it is noteworthy that these five miRNAs were associated by the web system to 57 cellular processes, including those in which HMGA proteins have been previously demonstrated to be involved, such as cell proliferation, differentiation, DNA-repair, chromatin modification and regulation of transcription (Fusco and Fedele, 2007; . The direct targeting of HMGA1 by miR-16 (Kaddar et al., 2009) , and of HMGA2 by Let-7a (Lee and Dutta, 2007) and miR196ab (De Martino et al., 2009a) was previously reported. Moreover, previous studies showed that miR-26a regulates HMGA2 expression (Lee et al., 2011) . The targeting sites of miRo'-predicted miRNAs on HMGA1 and HMGA2 3 0 -UTR are represented in Figure 1 . Then, to validate that HMGA1 and HMGA2 were targets of the selected microRNAs, MEG-01 cells, which express significant levels of both HMGA1 and HMGA2 proteins, were transfected with miR-15a, miR-16, miR-26a, miR-196a2 and Let-7a synthetic precursors, and HMGA protein levels were evaluated after 72 h by western blotting ( Figure 2a To validate the direct inhibition of HMGA proteins by these miRNAs, we used two pGL-3-CTRL vectors containing the HMGA1 or HMGA2 3 0 -UTR cloned downstream the firefly luciferase gene. These reporter vectors were transfected in MEG-01 cells along with synthetic precursor of miR-15, miR-16, miR-26a, miR-196a2 and Let-7a, and luciferase activity was assessed 24 h after the transfection. As shown in Figures 2c and d , overexpression of all the predicted HMGA-targeting miRNAs significantly reduced luciferase activity, demonstrating that the inhibition of HMGA protein expression by these miRNAs was dependent on their direct binding to the 3 0 -UTR of HMGA1 and HMGA2. Moreover, as our findings indicate that miR-15 was able to target both HMGA mRNAs, we also performed luciferase assays using pGL-3-CTRL vectors containing the HMGA1 or HMGA2 3 0 -UTR where the miR-15 and miR-16 targeting sites were deleted. Our results show that both HMGA1 and HMGA2 3 0 -UTR deletion mutants were not affected by miR-15 or miR-16 transfection (Supplementary Figure 1 ).
Taken together, our data clearly demonstrate that both HMGA proteins are direct targets of miR-15, miR-16, miR-26a, miR-196a2 and Let-7a. (Finelli et al., 2002) and in a subset of NFPA (Pierantoni et al., 2005) , whereas neither rearrangement nor amplification of the HMGA1 locus has been detected in human pituitary adenomas.
Then, the next step of our work was to analyze the expression of miR-15, miR-16, miR26a, miR-196a2 and Let-7a in a panel of 41 human pituitary adenomas, including 14 prolactinomas, 9 GH pituitary adenomas and 18 NFPA, by qRT-PCR. As shown in Figures 3a-e , all the selected HMGA-targeting miRNAs were drastically reduced in almost all the analyzed human pituitary adenomas, regardless of the histotype, when compared with the normal pituitary gland. Consistently, with the downregulation of these HMGA-targeting miRNAs that act also at mRNA level, an increase in the HMGA1 and HMGA2-specific mRNAs was observed in all the analyzed pituitary adenomas. In fact, the analysis of the HMGA1 and HMGA2 expression in the same samples studied herein for miRNA expression has been already reported in another recent study from our group (De Martino et al., 2009b) .
This result further suggests that reduced levels of HMGA-targeting miRNAs could represent a novel potential mechanism accounting, at least in part, for HMGA upregulation in human pituitary adenomas.
HMGA-targeting miRNAs negatively regulate pituitary cell proliferation
To investigate the functional role of HMGA-targeting miRNA downregulation in pituitary tumorigenesis, we determined the effects of the overexpression of these miRNAs on the cell growth of a GH/PRL rat pituitary cell line (GH3), which expresses high levels of HMGA1 but not of HMGA2.
The overexpression of HMGA-targeting miRNAs was achieved by transfecting different expression vectors (pMIRNA1) containing the precursor sequences of the miRNAs of our interest and the gene encoding the green fluorescent protein (GFP), in order to identify the efficiently transfected cells. As far as the expression Second, we analyzed the growth and the viability of GH3 cells following the overexpression of HMGAtargeting miRNAs. GH3 cells were transiently transfected with the synthetic precursors of miR-15, miR-16, miR-26a, miR-196a2 and Let-7a, and counted each day for 4 days. Figures 5a-d show that the growth rate of GH3 following the transfection of the HMGAtargeting miRNAs was lower compared with the cells transfected with the scrambled miRNA. Similar results were also obtained by transfecting synthetic precursors of miR-15, miR-16, miR-26a, miR-196a2 and Let-7a in MEG-01 cells (Supplementary Figure 2A) . Moreover, GH3 cells were also transfected during the seeding in 96-wells, and cell viability was measured by XTT proliferation assay 24 and 72 h following the transfection. As shown in Figure 5e , GH3 cells overexpressing HMGAtargeting miRNAs displayed, at 72 h, a lower number of viable cells compared with the empty vector-transfected cells. Third, we performed a colony assay co-transfecting the pMIRNA miR-expression vectors or the corresponding empty vector in GH3 cells along with a pBABE-Puro plasmid, containing the puromycin-resistance gene. Cells were cultured in puromycin-containing medium, and 15 days after the transfection the number of GFP-positive colonies was counted. As shown in Figure 5f and Supplementary Figure 3 , the transfection of each HMGA-targeting miRNA led to a drastic reduction of the number of colonies in comparison with the GH3 cells transfected with the empty vector. The same experiment was also performed co-transfecting the pMIRNA miR-expression vectors or the corresponding empty vector in MEG-01 cells. Interestingly, HMGAtargeting miRNAs reduced the colony formation ability also in this cellular context, even though the inhibitory effects were less drastic than those observed on pituitary GH3 cells (Supplementary Figure 2B) .
These results indicate that HMGA-targeting miRNAs are able to impair cell growth, and that they have a critical role in the control of pituitary cell proliferation.
Discussion
Overexpression of HMGA proteins is a common feature of human pituitary tumors. Indeed, it has been shown that HMGA2 gene is frequently amplified and overexpressed in human prolactinomas (Finelli et al., 2002) and, less often, in NFPAs (Pierantoni et al., 2005) , and overexpression of the HMGA1 gene has been constantly found in human pituitary adenomas (De Martino et al., 2009b; Wang et al., 2010) . Accordingly, (Fedele et al., , 2005 , suggesting that both these genes might be considered as specific oncogenes for pituitary cell transformation .
Several studies have widely explored the potential mechanisms of HMGA-dependent pituitary oncogenesis, and our group has demonstrated the involvement of HMGA proteins in the positive regulation of E2F1 activity (Fedele et al., 2006) and Ccnb2 expression (De Martino et al., 2007) resulting in pituitary cell cycle dysregulation and development of pituitary adenomas. However, the so far identified cytogenetic alterations (gene amplifications, chromosome overrepresentation or formation of derivative chromosomes) affecting HMGA1 and HMGA2 loci or the chromosomes where HMGA genes are located have not been detected in all the human pituitary adenomas even though almost all of them overexpress the HMGA proteins. Therefore, in the present study, we propose that overexpression of HMGA1 and HMGA2 in pituitary tumors might be dependent on the downregulation of HMGA-targeting miRNAs. Indeed, by using the miRo' bioinformatic tool for the prediction of miRNA-targeting sites, we identified miR-15, miR-16, miR-26ab, miR-196ab and Let-7a targeting sites on the 3 0 -UTRs of both HMGA1 and HMGA2. The direct targeting of HMGA1 by miR-16 (Kaddar et al., 2009) , and of HMGA2 by Let-7a Dutta, 2007) and miR-196a2 (De Martino et al., 2009a) has been previously described. Moreover, reduced levels of HMGA2 upon miR-26a transfection were also observed (Lee et al., 2011) . However, our present results clearly indicate that miR-16 is also able to directly target HMGA2, and that Let-7a and miR-196a2 target HMGA1. Finally, we first demonstrate the direct targeting of both HMGA genes by miR-26a and miR-15. It is noteworthy that all these HMGA-inhibiting miRNAs are able to affect the stability of the HMGA1 and HMGA2-specific mRNAs.
Based on these findings, we analyzed the expression levels of HMGA-targeting miRNAs in a panel of 41 human pituitary adenomas including different histotypes. Our data show that all the analyzed miRNAs resulted strongly downregulated in all the samples analyzed, regardless of the pituitary tumor histotype, and their expression is inversely correlated with that of the HMGA genes.
These results are in agreement with previously published data indicating the downregulation of miR-15/16 (Bottoni et al., 2005) and of Let-7a (Qian et al., 2009) 
in human pituitary adenomas.
Transfection experiments demonstrated that HMGAtargeting miRs are able to reduce HMGA1 levels also in GH3, a rat GH/PRL pituitary cell line, and that all the analyzed HMGA-targeting miRNAs significantly reduced cell growth. These results were also confirmed by colony assay experiments showing that GH3 cells transfected with the HMGA-targeting miRNAs did not form colonies, unlike the empty vector-transfected cells, but remained in a single-cell state. These data suggest that HMGA-targeting miRNAs are able to negatively regulate the pituitary cell cycle progression through the downregulation, at least in part, of HMGA proteins, whose overexpression, as discussed above, results in pituitary cell cycle dysregulation. These results present potential clinical implication, suggesting a new therapeutic approach for the most aggressive forms of pituitary adenomas based on the downregulation of HMGA proteins through the restoration of HMGA-targeting miRNAs. Moreover, as HMGA proteins have been found overexpressed in almost all human malignant neoplasias, where their abundance correlates with a poor prognosis (Fusco and Fedele, 2007) , it is likely that downregulation of HMGA-targeting miRNAs might be also involved in the pathogenesis of several highly aggressive human malignancies, and, therefore, a miRNA-based abrogation of HMGA expression could represent a novel approach for the therapy of human neoplasias.
Materials and methods
Cell lines and transfections MEG-01 were cultured in Rosewell Park Memorial Institute medium containing 10% fetal bovine serum supplemented with penicillin and streptomycin. GH3 cells were grown in Dulbecco's Modified Eagle medium containing 10% fetal bovine serum supplemented with penicillin and streptomycin. Cell lines were grown in a humidified atmosphere of 95% air and 5% CO2, at 37 1C. For transfection of miRNA oligonucleotides, cells were transfected with 50 nmol/ml pre-miR miRNA precursors or a control non-targeting scrambled oligonucleotides (Ambion, Austin, TX, USA) using siPORT neoFX Transfection Agent (Ambion). For pMIRNA1 expression vectors, cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions.
Plasmids and constructs
The 3 0 -UTR region of HMGA2 gene, including binding sites for miR-15, miR16, miR26ab, miR-196a and let-7a was previously described (De Martino et al., 2009a) . The 3 0 -UTR region of the HMGA1 gene, including binding sites miR-15, miR16, miR26ab, miR-196a and let-7a was amplified by PCR from human genomic DNA by using the following primers:
The amplified fragment was cloned into pGL3-Control Firefly luciferase vector (Promega, Fitchburg, WI, USA) at the XbaI site immediately downstream from the stop codon of luciferase. The Renilla luciferase vector (pRL-CMV) was purchased from Promega. MiRNA Precursor Constructs expressing the miR-15/ 16 cluster, miR-26a, miR-196a2 and let-7a under the transcriptional control of the CMV promoter and the GFP gene were purchased from SBI System Biosciences (Mountain View, CA, USA). HMGA1 and HMGA2 3 0 -UTR deletion mutants, where the miR-15/16 targeting sites were deleted, were generated by site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis Kits (Stratagene, Santa Clara, CA, USA), according to the manufacturer's instructions. Primers used were:
Protein extraction, western blotting and antibodies Cells were lysed in lysis buffer containing 1% NP40, 1 mM EDTA, 50 mM Tris-HCl (pH 7.5) and 150 mM NaCl, supplemented with complete protease inhibitors mixture (Roche, Branford, CT, USA). Total proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Amersham, Piscataway, NJ, USA). Membranes were blocked with 5% non-fat dry milk and incubated with anti-HMGA1 and anti-HMGA2 polyclonal antibodies, previously described (Pierantoni et al., 2001; Fedele et al., 2006) .
Luciferase target assays MEG-01 cells were co-transfected in 12-well plates with the modified firefly luciferase vectors described above, along with the Renilla luciferase reporter plasmid and the RNA oligonucleotides. Firefly and Renilla luciferase activities were measured 24 h after transfection with the Dual-Luciferase Reporter Assay System (Promega). Firefly activity was normalized to Renilla activity as the control of transfection efficiency. Data reported are the average þ s.d. of three independent experiments performed in triplicate.
Tissue collection and RNA isolation Pituitary adenomas were obtained from patients operated by E Jouanneau Service de Neurochirurgie U300, GHE Hospices Civils de Lyon. The tumors were selected from the pathological collection of one of us (JT). For each tumor, fragments were fixed in the Bouin-Holland fluid and embbeded in paraffine for pathological diagnosis, including immunocytochemistry. From the results of pituitary hormone immunoreactivity, the tumors were classified according to the WHO classification 2004 into GH-, PRL-, ACTH-, TSH-and gonadotropin-adenomas. Other fragments were immediately frozen and stored at À80 1C (Neurobiotec bank, Lyon, France). We declare that informed consent for the scientific use of biological material was obtained from all patients.
Total RNA isolation from human-pulverized tumors was performed with TRIzol reagent (Invitrogen) according to manufacturer's instructions. Three samples of total RNA from human normal pituitary glands obtained at autopsies were used as controls. The integrity of the RNA was assessed by denaturing agarose gel electrophoresis (virtual presence of sharp 28S and 18S bands).
Reverse transcription and (qRT-)PCR Reverse trascription and qRT-PCR for mature miRNA was carried out according to manufacturer's instructions of the miScript System Kits (Qiagen, Valencia, CA, USA). Reactions contained miScript Primer Sets (Qiagen), specific for each analyzed miR and U6 (used to normalize RNA levels). qRT-PCR analysis for HMGA1 and HMGA2 gene expression was performed as already described (De Martino et al., 2009b) . To calculate the relative expression levels we used the 2-DDCT method (Livak and Schmittgen, 2001) . Each reaction was carried out in triplicate and the average þ s.d. was reported. Primers specific for the glucose-6-phosphate dehydrogenase (G6PD) were used for normalization of qRT-PCR data. The following primer sequences were used to amplify the indicated genes:
hsa-HMGA1-F 4 0 -CAACTCCAGGAAGGAAACCA-3 
